StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Saturday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Trading Down 1.3 %

NASDAQ:TXMD opened at $1.50 on Friday. The stock has a 50 day moving average of $1.63 and a two-hundred day moving average of $1.79. TherapeuticsMD has a 12 month low of $1.43 and a 12 month high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.